Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor Resistance, GenoSure
The hepatitis C virus (HCV) is the most common cause of non-A, non-B hepatitis and accounts for >60% of all chronic cases of hepatitis. The Centers for Disease Control and Prevention (CDC) estimates there are approximately 17,000 new infections each year in the US and a total of 3.2 million chronic carriers. Of the newly infected, less than 25% will spontaneously eliminate the virus, with the remaining 75 - 85% becoming chronically infected. Patients that are chronically infected with HCV are at greater risk for developing chronic liver disease, cirrhosis, and hepatocellular carcinoma. Treatment exists for HCV and is often effective in totally eliminating the virus from the patient. Each year in the US 8,000 - 10,000 people die from HCV-related complications.
Infection is typically through contact with infected blood (i.e., IV drug abuse, needle sticks), blood products (prior to 1992), from mother to child, or contact with positive secretions. It has been shown that it is not easily spread via sexual contact. Other modes of HCV infection include dialysis, tattoos, and recipients of blood or organs from an HCV donor; however, these are fairly rare.
There are different forms of HCV that are based on subtle differences in the genetic material of the virus, which for HCV is RNA (instead of the more common DNA). These subtle differences in the RNA genome are used to classify HCV into separate types, termed genotypes. For HCV, there are six major genotypes that are designated types 1 - 6. These are further broken down into subtypes (1a, 1b, 2a, 2b, etc.), with over 50 subtypes identified. Genotypes are important because they have been shown to respond differently to the anti-viral agents used to treat HCV, with genotypes 2 and 3 responding better to therapy than genotypes 1 or 4. Treatment is also longer for genotypes 1 or 4 (12 months) compared to genotypes 2 or 3 (6 months). Therefore, determining the genotype aids the physician in determining the appropriate treatment and duration for anti-HCV therapy.
This assay is performed using serum or plasma from an infected individual. Results of this assay should be used in conjunction with the HCV viral load and other laboratory tests as an assessment for the initiation and duration of anti-HCV therapy.
- To determine HCV genotype upon diagnosis
- To evaluate patients being considered for therapy
Negative (Not Detected)
Serum (SST), Plasma ACD (Yellow), PPT (White).
Stability
- Ambient: 1-3 days
- Refrigerated: 5-7 days
- Frozen: 30 days
- J Hepatol. 2011 Dec 13. [PMID: 22173157]
- Arch Pathol Lab Med. 2002;126:285. [PMID: 11860301]
- Future Microbiol. 2006 Jun;1:103-12. [PMID: 17661689]
- Antivir Ther. 2005;10(1):1-11. [PMID: 15751759]
- J Clin Microbiol. 2002;40:4407. [PMID: 12454127]
- Lancet. 2003;362:2095. [PMID: 14697814]
- J Clin Virol. 2005;34:108. [PMID: 16157261]
- Nature. 2005 Aug 18;436(7053):939-45. [PMID: 16107833]
- Semin Liver Dis. 2009 Feb;29(1):53-65. Epub 2009 Feb 23. [PMID: 19235659]